Tudor Investment Corp
BRNS

Tudor Investment Corp’s Barinthus Biotherapeutics BRNS Stock Holding History

Tudor Investment Corp’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-266,927
Closed -$1.19M – 2320
2022
Q2 		$1.19M Buy
+266,927
New +$1.29M 0.03% 788
2021
Q4 		– Sell
-378,260
Closed -$5.73M – 2417
2021
Q3 		$5.73M Sell
378,260
-42,059
-10% -$639K 0.09% 226
2021
Q2 		$6.01M Buy
+420,319
New +$6.22M 0.11% 164

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tudor Investment Corp's BRNS Position: Q3 2022 in Review

Tudor Investment Corp sold out of Barinthus Biotherapeutics (BRNS) in Q3 2022, closing a stake of 266,927 shares — an estimated $1.19M sold.

Tudor Investment Corp first reported a position in BRNS in Q2 2021 and held it in 3 quarters. The position peaked at $6.01M in Q2 2021. 11 funds tracked by Wall St. Rank hold BRNS as of Q3 2022.

  • Tudor Investment Corp reported no remaining Barinthus Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Tudor Investment Corp sold 266,927 Barinthus Biotherapeutics shares in Q3 2022, an estimated $1.19M.
  • Tudor Investment Corp first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 3 quarters.
  • Tudor Investment Corp's Barinthus Biotherapeutics position peaked at $6.01M in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2022.

Based on Tudor Investment Corp's 13F filing for Q3 2022, filed 14 Nov 2022.